The Diabetes Canada 2018 Clinical Practice Guidelines emphasize individualized blood-pressure targets, regular monitoring, and first-line therapies such as ACE inhibitors or ARBs for patients with diabetes, particularly those with albuminuria or cardiovascular risk factors [3,10,12]. The gene discussed is ACE; the disease is diabetes mellitus.